Venous thromboembolism in metastatic pancreatic cancer

• DOI: 10.1111/ejh.13955
• Publication Date: 2023-03-21T03:50:06Z
• Authors: Lauren Laderman; Krishnalatha Sree...; Ramesh K. Pandey; Elizabeth Handorf; Aryeh Blumenreich; Kristen A. Sorice; Shannon M. Lynch; Khadija Cheema; Lavanya Nagappan; Iberia R. Sosa; Efrat Dotan; Namrata Vijayvergia
• Keywords: Male; Pancreatic Neoplasms; Risk Factors; Incidence; Humans; Anticoagulants; Female; Venous Thromboembolism; 3. Good health; Retrospective Studies

Pancreatic cancer (PC) carries a high risk of venous thromboembolism (VTE). Several assessment models (RAMs) predict benefit thromboprophylaxis in solid tumors; however, none are verified metastatic pancreatic (mPC).A retrospective mPC cohort treated at an academic center from 2010 to 2016 was investigated for VTE incidence (VTEmets). Multivariable regression analysis used assess multiple factors. Overall survival (OS) compared between groups with and without VTE. Survival analyzed using Kaplan-Meier plots Cox proportional hazards regressions.400 patients (median age 66; 52% males) were included. 87% had performance status ECOG 0-1; 70% advanced stage PC diagnosis. Incidence VTEmets 17.5%; median time occurrence 3.48 months after started occurrence. Median OS 10.5 vs. 13.4 non-VTE group. Only (OR 3.7, p = .001) correlated increased risk.The results suggest significant burden. predicts poor outcomes the point Advanced disease is strongest factor. Future studies needed define stratification, benefit, choice thromboprophylaxis.